Matrix metalloproteinase 12 is an independent prognostic factor predicting postoperative relapse of conventional renal cell carcinoma - a short report.
- Resource Type
- Academic Journal
- Authors
- Beres B; Department of Urology, Medical School, University of Pecs, Pecs, Hungary.; Yusenko M; Institute of Biochemistry, University of Muenster, Muenster, Germany.; Peterfi L; Department of Urology, Medical School, University of Pecs, Pecs, Hungary.; Kovacs G; Department of Urology, Medical School, University of Pecs, Pecs, Hungary. g.kovacs@gmx.de.; Medical Faculty, Ruprecht-Karls-University, Heidelberg, Germany. g.kovacs@gmx.de.; Banyai D; Department of Urology, Medical School, University of Pecs, Pecs, Hungary.
- Source
- Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE
- Subject
- Language
- English
Purpose: Approximately 15% of clinically localised conventional renal cell carcinomas (cRCC) develop metastases within 5 years of follow-up. Sarcomatous cRCC is a highly malignant cancer of the kidney. The aim of our study was to identify biomarkers for estimating the postoperative progression of cRCCs.
Methods: Global microarray-based gene expression analysis of RCCs with and without sarcomatous changes revealed that a high MMP12 expression was associated with a sarcomatous histology. Additionally, we analysed MMP12 expression using a multi-tissue array comprising 736 cRCC patients without metastasis at the time of surgery. The median follow-up time was 66 ± 29 months.
Results: Immunohistochemistry revealed MMP12 expression in 187 of 736 cRCCs with good follow-up data. Subsequent Kaplan-Meier analysis revealed that patients with MMP12 positive tumours exhibited a significantly shorter tumour-free survival (p < 0.001). In multivariate Cox regression analysis a weak to strong MMP12 expression indicated a 2.4-2.8 times higher risk of postoperative tumour relapse (p < 0.001; p < 0.003, respectively).
Conclusions: MMP12 may serve as a biomarker to estimate postoperative cRCC relapse and as a possible target for penfluridol therapy.
(© 2021. The Author(s).)